MSD has commenced the Phase III trial to assess zilovertamab vedotin combined with R-CHP to treat individuals with previously ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

1 215 728 2674 Fax: +1 215 728 3639 [email protected] Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...

6% had high-grade B-cell lymphoma (double hit or triple hit), 14% had mantle cell lymphoma, 14% had Richter transformation, and 8% had other indolent lymphoma. The median number of previous ...

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...